Protara Therapeutics (TARA) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Protara Therapeutics (NASDAQ: TARA) in the last few weeks:

• 5/20/2026 – Protara Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $25.00 to $28.00. They now have an “outperform” rating on the stock.
• 5/20/2026 – Protara Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/20/2026 – Protara Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 5/20/2026 – Protara Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 5/16/2026 – Protara Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/14/2026 – Protara Therapeutics had its price target lowered by JPMorgan Chase & Co. from $27.00 to $26.00. They now have an “overweight” rating on the stock.
• 4/29/2026 – Protara Therapeutics had its price target raised by HC Wainwright from $23.00 to $27.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Protara Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Protara Therapeutics

In other news, insider Jacqueline Zummo sold 22,598 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total transaction of $118,865.48. Following the completion of the transaction, the insider directly owned 95,961 shares in the company, valued at approximately $504,754.86. The trade was a 19.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.60% of the company’s stock.

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.